Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating The Safety And Tolerability Of Intravenous KK2269 Monotherapy And Combination Therapy With Docetaxel In Adult Participants With Solid Tumors
Scottsdale/Phoenix, AZ
Jacksonville, FL
This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary objective is to assess the safety and tolerability of KK2269.
In Part 2, only participants with gastric adenocarcinoma, GEJ adenocarcinoma, esophageal adenocarcinoma, or NSCLC who have experienced at least one systemic therapy will be enrolled. In Part 2, the primary objective is to assess the safety and tolerability of KK2269 in combination with docetaxel and to determine the recommended dose(s) and dose interval(s) of KK2269 in combination with docetaxel for subsequent studies.
In both Part 1 and Part 2, participants who refuse to undergo standard therapy are also eligible.
-
A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, And Pharmacokinetic Study Of Q901 Administered Via Intravenous Infusion In Adult Patients With Selected Advanced Solid Tumors With A Cohort Expansion At The Recommended Phase 2 Dose
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of part one of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and safety profile of Q901 monotherapy when administered via intravenous (IV) infusion once-weekly (QW) for 4 weeks and once every 2 weeks (Q2W) thereafter. Also, to establish for future clinical development the recommended Phase 2 dose (RP2D) of Q901 monotherapy when administered via IV infusion QW for 4 weeks and Q2W thereafter.
The purpose of part two of this study is to evaluate safety and tolerability and evidence of anticancer activity of Q901 as monotherapy and in combination with pembrolizumab. In Part 2 Cohort 1, an expansion phase at the established RP2D will be undertaken in participants with selected advanced solid tumors. In Part 2 Cohort 2, a safety run in and expansion phase will be undertaken with Q901 at the RP2D administered in combination with pembrolizumab (400 mg Q6W) in participants with advanced solid tumors.
-
Obesity And Inflammation Impact Immunotherapy Outcomes In Renal Cancer
Scottsdale/Phoenix, AZ
The purpose of this study is to determine the extent to which immunotherapy failure in kidney cancer patients with obesity is associated with prolonged, body-wide inflammation. Hypothesis: In patients with obesity, high sustained inflammation will be associated with poor immunotherapy outcomes, high inflammation that resolves during therapy will be associated with better outcomes, and sustained low inflammation will be associated with the best therapy outcomes. These general trends will also hold true for non-obese RCC patients, although the magnitude of the response rates may be shifted.
Contact Us for the Latest Status
Closed for Enrollment
-
A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating The Safety And Tolerability Of Intravenous KK2269 Monotherapy And Combination Therapy With Docetaxel In Adult Participants With Solid Tumors
Rochester, MN
This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary objective is to assess the safety and tolerability of KK2269.
In Part 2, only participants with gastric adenocarcinoma, GEJ adenocarcinoma, esophageal adenocarcinoma, or NSCLC who have experienced at least one systemic therapy will be enrolled. In Part 2, the primary objective is to assess the safety and tolerability of KK2269 in combination with docetaxel and to determine the recommended dose(s) and dose interval(s) of KK2269 in combination with docetaxel for subsequent studies.
In both Part 1 and Part 2, participants who refuse to undergo standard therapy are also eligible.
-
A Phase 1/2, Open-Label Study To Investigate The Safety, Tolerability, Pharmacokinetics, Biological And Clinical Activity Of DF9001 As A Monotherapy And In Combination With Nivolumab In Patients With Advanced Solid Tumors, And Expansion In Selected Indications
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to determine if a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). A combination therapy cohort will be opened for enrollment, DF9001 + nivolumab. The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors.
-
An Open-label, Multicenter Phase 1/2 Study To Evaluate The Safety And Efficacy Of AB-2100 In Patients With Recurrent Advanced Or Metastatic Clear-cell Renal Cell Carcinoma (CcRCC)
Scottsdale/Phoenix, AZ
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
-
Molecular Characterization Of Renal Cell Carcinomas And Melanomas
Scottsdale/Phoenix, AZ
Rochester, MN
The purpose of this study is to collect blood samples from Mayo Clinic patients with a diagnosis of Renal Cell Carcinoma (RCC) or Melanoma. The blood samples will be used to study immune cells which are the cells in our blood involved in protecting the body from disease and foreign invaders. The blood samples may also be used for future research of Renal Cell Carcinoma (RCC) or Melanoma at Mayo Clinic and future research at Mayo Clinic to learn about, prevent, or treat other health problems.
.